Sun Pharmaceutical Industries Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is FEBUXOSTAT, with a corresponding US DMF Number 26722.
Remarkably, this DMF maintains an Active status since its submission on December 29, 2012, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of April 22, 2013, and payment made on December 28, 2012, indicating their dedication to facilitating drug approvals, Categorized as Type II